Strattera Dose for Children and Teens: Weight-Based Guide

Strattera (atomoxetine) pediatric dosing is fundamentally different from adult dosing — it's weight-based rather than fixed-dose, requires careful titration based on individual child's body weight, has specific maximum doses calibrated to child size, and requires ongoing growth monitoring because atomoxetine can affect appetite and growth velocity in some children. The standard pediatric protocol starts at 0.5 mg/kg/day for the first 4 days, then titrates to a target dose of 1.2 mg/kg/day after one week, with maximum dose of 1.4 mg/kg/day or 100 mg total — whichever is lower. This means a 25 kg (55 lb) child starts at 12.5 mg daily, titrates to 30 mg target, with maximum 35 mg (since 35 mg < 100 mg). A 60 kg (132 lb) adolescent starts at 30 mg daily, titrates to 72 mg target (often rounded to 60-80 mg available capsule), with maximum 84 mg (rounded to 80 mg). FDA approves Strattera for children ages 6 and older with ADHD; not approved under age 6. The medication is commonly prescribed throughout childhood and adolescence as both monotherapy and combination treatment for ADHD.

This guide provides comprehensive information about Strattera pediatric dosing for parents, caregivers, school personnel, and adolescent patients. We address weight-based dosing principles fundamental to pediatric atomoxetine prescribing, the 0.5 mg/kg starting dose with calculation examples, the 1.2 mg/kg target dose representing typical therapeutic effect, the 1.4 mg/kg or 100 mg maximum dose constraints, age 6-12 specific considerations (younger children, capsule swallowing, behavior monitoring), age 13-17 considerations (adolescent autonomy, growth spurts, academic transitions, social context), the growth monitoring protocol essential for pediatric atomoxetine treatment, weight-to-dose conversion reference covering common weight ranges, school communication guide for medication management at school, pediatric-specific side effect profile, and the bottom-line framework for safe effective pediatric Strattera use.

📏 Weight-Based Dosing Explained

Why pediatric dosing differs fundamentally from adult dosing:

• Body size variation: Children's weights range from 18 kg (6-year-old) to 70+ kg (large 17-year-old) — 4x range.
• Pharmacokinetic scaling: Drug distribution volume and clearance correlate with body weight in growing patients.
• Therapeutic window optimization: Weight-based dose ensures adequate plasma levels without excessive exposure.
• Safety margin: Avoids under-dosing larger children and over-dosing smaller children.
• FDA-approved pediatric protocol based on extensive clinical trial data.

The pediatric atomoxetine math:

• Starting dose calculation: Child's weight (kg) × 0.5 mg/kg = starting daily dose (round to nearest capsule strength).
• Target dose calculation: Child's weight (kg) × 1.2 mg/kg = target daily dose (round to nearest capsule strength).
• Maximum dose calculation: Child's weight (kg) × 1.4 mg/kg = maximum daily dose, capped at 100 mg total.
• For children >70 kg: Adult dosing protocol applies (40 mg → 80 mg → 100 mg max).

Available capsule strengths and rounding:

• Available strengths: 10, 18, 25, 40, 60, 80, 100 mg capsules.
• Cannot be split: Capsules sealed for absorption properties; rounding to nearest strength necessary.
• Round to clinically appropriate: Slight under-dose generally preferred to over-dose if intermediate calculation.
• Example rounding: 36 mg calculated → round to 40 mg (clinically equivalent, closer to therapeutic range).
• Combination dosing rare: Generally single capsule once daily.

Weight measurement importance:

• Recent accurate weight needed for calculation.
• Growth changes dose calculations — pediatric patients gain weight.
• Periodic re-weighing at every visit.
• Dose adjustment as child grows: Particularly important during growth spurts.
• Underweight or overweight considerations: Use actual body weight, not adjusted ideal weight.

Why not just use adult protocol for all children:

• Smaller children would be overdosed at adult fixed doses.
• 40 mg starting dose for 20 kg child = 2 mg/kg — far exceeds maximum 1.4 mg/kg.
• Severe side effects would result from inappropriate fixed dosing.
• Pediatric safety requires weight-based approach.

🌱 Starting Dose: 0.5 mg/kg

The 0.5 mg/kg/day pediatric starting dose protocol:

• Duration: Minimum 4 days at starting dose before titration (some protocols 7 days like adult).
• Purpose: Tolerance development to early side effects before therapeutic dose.
• Calculation: Weight in kg × 0.5 mg = starting daily dose.
• Rounding: To nearest available capsule strength.
• Once daily dosing: Morning generally preferred for school day functioning.

Starting dose examples with rounding:

• 18 kg child: 9 mg calculated → 10 mg capsule.
• 22 kg child: 11 mg calculated → 10 mg capsule.
• 25 kg child: 12.5 mg calculated → 10-18 mg capsule (clinical judgment).
• 30 kg child: 15 mg calculated → 18 mg capsule (closer to calculation).
• 35 kg child: 17.5 mg calculated → 18 mg capsule.
• 40 kg child: 20 mg calculated → 18-25 mg capsule.
• 50 kg adolescent: 25 mg calculated → 25 mg capsule.
• 60 kg adolescent: 30 mg calculated → 25-40 mg capsule.
• 70 kg adolescent: 35 mg calculated → 40 mg capsule (often use adult 40 mg starting).

Why start low pediatrically:

• Smaller body mass means same dose produces higher relative exposure.
• Side effects often more intense initially in children.
• Behavioral effects: Children may have more pronounced mood/behavior reactions.
• Family adjustment: Parents need to recognize and report side effects.
• School coordination: Time for teachers to observe and report.

Common pediatric starting concerns:

• Appetite reduction: Most common; can be significant.
• Nausea or stomach upset: Particularly mornings without food.
• Fatigue or sedation: May affect school participation.
• Mood changes: Irritability, sadness, or behavioral changes — particularly monitor per FDA Black Box for suicidal ideation in adolescents.
• Sleep changes: Either insomnia or excessive sleepiness.

Starting dose monitoring schedule:

• Day 1-3 most intense observation: Watch for severe side effects, mood changes.
• Parents check in with prescriber day 3-4 by phone if concerns.
• Day 7 visit or call for titration decision.
• School communication: Teacher observations of child during starting period.
• Daily mood/behavior tracking recommended.

🎯 Target Dose: 1.2 mg/kg

The 1.2 mg/kg/day target therapeutic dose:

• Calculation: Weight in kg × 1.2 mg = target daily dose.
• Timing of titration: Day 4-7 after starting dose, depending on protocol.
• Standard therapeutic dose for most pediatric patients.
• Full therapeutic effect timeline: 4-6 weeks at target dose for full assessment.
• Round to available capsule strength.

Target dose examples with rounding:

• 20 kg child: 24 mg calculated → 25 mg capsule.
• 25 kg child: 30 mg calculated → 25 mg capsule (or 40 mg if symptomatically warranted).
• 30 kg child: 36 mg calculated → 40 mg capsule (most common round).
• 35 kg child: 42 mg calculated → 40 mg capsule.
• 40 kg child: 48 mg calculated → 40-60 mg capsule (clinical judgment).
• 50 kg adolescent: 60 mg calculated → 60 mg capsule.
• 60 kg adolescent: 72 mg calculated → 80 mg capsule (or 60 mg if side effects).
• 70 kg adolescent: 84 mg calculated → 80 mg capsule (use adult protocol).
• 80+ kg adolescent: Use adult dosing (80 mg target).

Reaching target dose:

• Most children should reach target by week 2.
• Side effects may briefly intensify with dose increase, then resolve.
• Continue at target for at least 4-6 weeks before evaluating therapeutic response.
• Adjust if needed based on response and tolerability.

Assessing therapeutic response at target dose:

• ADHD symptom improvement: Attention, hyperactivity, impulsivity.
• School performance: Grades, behavior reports, focus during instruction.
• Homework completion: Independence, focus, task initiation.
• Family functioning: Compliance with requests, emotional regulation, sibling interactions.
• Social functioning: Peer interactions, friendship maintenance.
• Self-esteem changes: Confidence improvements with treatment success.

⛔ Maximum: 1.4 mg/kg or 100mg

Maximum pediatric dose limits:

• Calculated maximum: Weight in kg × 1.4 mg.
• Absolute maximum: 100 mg total daily, regardless of weight.
• Use whichever is LOWER for individual patient.
• Children up to 71 kg: Calculated maximum (1.4 mg/kg) applies.
• Children >71 kg: 100 mg total daily cap applies (1.4 mg/kg would exceed).

Maximum dose calculations:

• 20 kg child: 28 mg maximum (1.4 × 20).
• 30 kg child: 42 mg maximum.
• 40 kg child: 56 mg maximum.
• 50 kg adolescent: 70 mg maximum.
• 60 kg adolescent: 84 mg maximum.
• 71 kg+ adolescent: 100 mg maximum (absolute cap).

When to consider maximum dose:

• Target dose (1.2 mg/kg) inadequate after 4-6 week trial.
• Some improvement but suboptimal at target dose.
• Side effects tolerable at target dose (room to escalate).
• Functional impairment persisting despite target dose.

When NOT to escalate to maximum:

• No response at target dose: Strattera may not be right medication.
• Significant side effects at target: Maximum will worsen.
• Growth concerns: Higher doses may further suppress appetite/growth.
• Cardiovascular concerns: Higher doses produce more cardiovascular stimulation.
• Mood concerns: FDA Black Box considerations.

Maximum dose monitoring:

• Cardiovascular assessment: BP, heart rate.
• Growth monitoring more frequent: Monthly weight, quarterly height initially.
• Side effect tracking.
• Mood and behavior monitoring.
• School performance assessment.

👦 Age 6-12 Considerations

Specific considerations for elementary school-aged children:

Age 6-8 (early elementary):

• Smallest pediatric patients — typically 18-30 kg.
• Starting doses very small: 10 mg capsule may be lowest practical starting.
• Capsule swallowing: May be challenging; cannot be opened or crushed.
• Behavioral observation: Parents and teachers primary observers — child can't verbalize side effects well.
• Mood changes: May manifest as behavioral changes; close monitoring needed.
• Growth particularly important at this age — most sensitive to appetite/growth effects.

Age 9-12 (older elementary, middle school transition):

• Larger children: Typically 30-50 kg.
• Better capsule swallowing generally.
• More verbal about side effects.
• School demands increasing: Treatment effectiveness for academic functioning important.
• Self-awareness developing: Child may notice ADHD symptoms and treatment effects.
• Peer comparisons: Stigma around medication may emerge.

Capsule administration challenges in younger children:

• Strattera capsules cannot be opened: Specific FDA warning — irritant to mucous membranes if opened.
• Capsule should be swallowed whole.
• Strategies for capsule swallowing: Practice with empty capsules, applesauce on tongue then pill, pill cup, lots of water, lying down techniques.
• Coordination with pediatrician: If child truly cannot swallow capsules, consider alternative ADHD medications (chewable, liquid, dissolving formulations).

School considerations for elementary age:

• School nurse coordination: Aware of medication if any school-administered.
• Teacher awareness: Of treatment and side effect monitoring.
• 504 plan or IEP considerations: Documentation of ADHD diagnosis and accommodations.
• Parent-teacher communication: About behavior and academic changes.
• Snack/meal timing: Decreased appetite consideration; ensure adequate nutrition.
• Bathroom needs: Some children develop urinary considerations.

Behavior monitoring in younger children:

• Mood changes: Sadness, irritability, withdrawn behavior.
• Aggression changes: Either improved or worsened.
• Sleep patterns: Initiation, duration, quality.
• Appetite: Specific foods, meal patterns, weight tracking.
• School behavior reports: Teachers' observations.
• Parent diary: Daily tracking valuable for follow-up visits.

👨 Age 13-17 Considerations

Adolescent-specific considerations:

Age 13-15 (middle school, early high school):

• Significant growth spurts: Body weight may change substantially; dose may need adjustment.
• Hormonal changes: Puberty affects many physiological systems.
• Mood vulnerability: Adolescent mood changes complicate medication assessment.
• FDA Black Box for suicidal ideation particularly relevant in adolescent age group.
• Social pressures increasing: Peer comparisons, body image, substance use exposure.
• Academic transitions: Increased academic demands; treatment effectiveness important.

Age 16-17 (older high school):

• Approaching adult body size: Often using adult dosing protocol if 70+ kg.
• Autonomy in treatment: Adolescent increasingly responsible for own medication adherence.
• College/career preparation: Treatment effectiveness for long-term functioning.
• Substance use considerations: Alcohol, cannabis, other substances relevant.
• Driving: Strattera effects on driving generally benign but relevant.
• Sexual activity: Potential side effects (rare in this age group but possible) relevant.

Adolescent autonomy considerations:

• Adolescent should understand why taking medication.
• Self-monitoring skills: Recognizing own symptoms and side effects.
• Communication with prescriber: Adolescent should have voice in treatment decisions.
• Adherence challenges: Forgetting doses, skipping intentionally, discontinuation.
• Privacy considerations: Confidentiality of treatment from peers.
• Transition to adult care: Around age 17-18; preparation needed.

Growth spurt dose adjustments:

• Adolescents can gain 10-20 kg over 1-2 years during growth spurts.
• Dose may need increase if weight gain significantly outpaces dose.
• Recalculate dose at each visit based on current weight.
• Common pattern: 50 kg adolescent on 60 mg → 65 kg adolescent may need 80 mg.
• Discuss at follow-up visits.

Mental health monitoring in adolescents:

• FDA Black Box warning for suicidal ideation particularly relevant in adolescents.
• Mood changes: Depression, anxiety, irritability monitoring.
• Behavioral changes: Withdrawal, isolation, risk-taking.
• Sleep changes: Disruption can affect mood.
• Substance use: Cannabis, alcohol can interact and affect mood.
• Open family communication: Encourage adolescent disclosure.
• Professional help: Therapy or counseling if mental health concerns emerge.

Substance use considerations:

• Alcohol: Don't combine with Strattera; affects mood, judgment.
• Cannabis: Increasingly common in adolescents; affects Strattera and ADHD treatment.
• Other substances: Various concerns.
• Honest communication with prescriber about substance use enables proper treatment management.
• Substance use counseling if needed.

📊 Growth Monitoring Protocol

Essential growth monitoring during pediatric Strattera treatment:

Why growth monitoring matters:

• Atomoxetine can decrease appetite particularly initially.
• Weight loss possible especially in early treatment.
• Growth velocity may be affected in some children.
• Catch-up growth typical if temporary growth slowdown.
• Long-term growth concerns documented for some children — close monitoring identifies issues early.

Monitoring schedule:

• Baseline: Height and weight before starting Strattera.
• Month 1: Weight check (height not necessary monthly).
• Months 2-3: Weight check.
• Every 3-6 months thereafter: Height and weight; track on growth chart.
• Annual growth chart review: Pediatrician plot on standardized growth chart.
• Body mass index (BMI) tracking over time.

Concerning growth patterns:

• Significant weight loss (>5% from baseline): Investigate cause; nutritional counseling.
• Failure to gain expected weight for age.
• Height growth velocity decreased (crossing percentile lines downward).
• BMI dropping into underweight range.
• Crossing two major growth percentiles downward warrants attention.

Interventions when growth concerns arise:

• Nutritional support: Calorie-dense foods, smaller more frequent meals, protein supplementation.
• Timing optimization: Take Strattera after breakfast rather than before.
• Treatment holidays: Some clinicians use weekend or summer holidays to allow catch-up growth (though Strattera doesn't have immediate withdrawal so holidays less straightforward than stimulants).
• Dose reduction consideration: Lower dose if growth concerns significant.
• Treatment continuation reassessment: Risk-benefit of continued treatment vs growth concerns.
• Endocrinology consultation: If significant growth concerns.

Long-term growth outcomes data:

• Studies show: Most children on long-term atomoxetine reach expected adult height with possible slight reduction.
• Catch-up growth: Common when treatment discontinued or dose adjusted.
• Individual variation: Some children significantly affected, others not at all.
• Family monitoring important beyond clinical visits.

Nutritional counseling for children on Strattera:

• Eat substantial breakfast before Strattera dose.
• Calorie-dense snacks available throughout day.
• Smoothies and milkshakes for nutrition when appetite reduced.
• Protein focus: Adequate protein for growth.
• Vitamin/mineral supplementation if dietary intake inadequate.
• Family dinner emphasis: Often best appetite later in day.
• Avoid forcing food: Mealtime battles counterproductive.
• Pediatric dietitian referral if significant nutrition concerns.

📋 Weight-to-Dose Conversion Reference

Comprehensive weight-based pediatric dosing reference:

🏫 School Communication Guide

Coordinating Strattera treatment with school:

Information to share with school:

• Diagnosis: Child has ADHD; receiving medical treatment.
• Medication name: Strattera (atomoxetine).
• Dosing schedule: Once daily, typically morning at home.
• Side effects to watch for: Decreased appetite, fatigue, mood changes.
• Behavior changes expected: Improved attention, possibly initially worse before better.
• Emergency contacts.

School nurse role:

• Usually no school-administered Strattera — typically morning dose at home.
• Awareness for any health issues arising during school day.
• Snack accommodations if decreased appetite.
• Bathroom needs if relevant.
• Communication channel for any concerns.

Teacher communication:

• General awareness of treatment without specific disclosure unless parent chooses.
• Behavior observation: Reporting changes to parents.
• Academic performance tracking: Grades, focus, participation.
• Treatment timeline understanding: 4-6 weeks for full effect.
• Patience with adjustment period.

504 plan or IEP considerations:

• 504 plan: Accommodations for ADHD without specialized instruction.
• IEP (Individualized Education Program): Specialized instruction if needed.
• Common accommodations: Extended time for tests, preferential seating, breaks during long activities, organizational support.
• Medication compatible with accommodations — together optimize student functioning.
• Annual review of accommodations as child progresses.

Parent-teacher conferences:

• Share treatment status in age-appropriate detail.
• Discuss behavior and academic progress.
• Get teacher feedback on treatment effectiveness.
• Coordinate strategies for school and home.
• Document for prescriber visits: Teacher observations valuable.

Privacy considerations:

• Medical information confidential: Schools cannot share without permission.
• Need-to-know basis: Only relevant school personnel informed.
• Child's preferences as they age: Adolescents may want more privacy from peers.
• HIPAA and FERPA considerations.

💊 Pediatric Side Effect Profile

Pediatric-specific side effects and considerations:

Most common pediatric side effects:

• Decreased appetite: Most common; often significant impact on nutrition.
• Stomach upset/nausea: Particularly in mornings; better with food.
• Fatigue/sleepiness: Can affect school participation.
• Headache: Common initially; usually resolves.
• Dizziness: With position changes.
• Mood changes: Irritability, sadness, withdrawn behavior.
• Sleep changes: Insomnia or excessive sleepiness.
• Weight loss: Particularly first few months.

Less common but important pediatric side effects:

• Suicidal ideation: FDA Black Box warning; particularly relevant adolescents 13-17.
• Aggression or behavioral changes: Either improved or worsened.
• Psychotic symptoms: Very rare; particularly in patients with predisposition.
• Mania: Rare; particularly in patients with mood disorder predisposition.
• Liver function abnormalities: Rare; jaundice or dark urine warrant immediate attention.
• Severe allergic reactions: Very rare.
• Cardiovascular issues: Generally minor; rarely concerning in healthy children.

Symptoms requiring immediate prescriber contact:

• Any expression of suicidal thoughts.
• Significant mood changes: Persistent sadness, severe irritability, withdrawal.
• Aggression escalation.
• Hallucinations or psychotic symptoms.
• Yellow skin/eyes or dark urine (liver concerns).
• Severe abdominal pain.
• Allergic reaction symptoms.
• Significant weight loss.
• Cardiovascular symptoms: Chest pain, severe palpitations, fainting.

Family monitoring approach:

• Daily behavior and mood observation.
• Weekly check-ins with child about how they're feeling.
• Sleep, appetite, mood, behavior diary.
• School communication for additional observation.
• Open conversation environment for child to share concerns.
• Regular prescriber follow-ups.

Side effect management strategies:

• Appetite: Substantial breakfast before dose; calorie-dense snacks; family dinner emphasis.
• Nausea: Take with food; smaller meals; avoid offending foods.
• Fatigue: Adequate sleep; consider morning dosing.
• Sleep: Sleep hygiene; consider dose timing.
• Mood: Open communication; professional help if needed.
• Headache: Hydration; usually resolves.

✨ Bottom Line

Strattera pediatric dosing is fundamentally weight-based, requiring careful calculation, titration, and ongoing growth monitoring. The Pediatric Weight Calculator Card establishes the formula: starting dose 0.5 mg/kg/day (rounded to nearest capsule strength), target dose 1.2 mg/kg/day after 7 days, maximum dose 1.4 mg/kg/day or 100 mg total daily (whichever is lower). Children >70 kg generally use adult protocol (40 mg → 80 mg → 100 mg). FDA-approved for age 6 and older only.

Weight-based dosing matters because children's body sizes vary 4x range (18 kg 6-year-old to 70+ kg 17-year-old) — fixed adult dosing would dangerously overdose smaller children. The calculation requires recent accurate weight at each visit, particularly during growth spurts. Round to available capsule strengths (10, 18, 25, 40, 60, 80, 100 mg) — capsules cannot be opened or crushed.

Starting dose 0.5 mg/kg/day for 4-7 days enables tolerance development before therapeutic dose. Common side effects in starting phase: decreased appetite (most common), nausea, fatigue, mood changes, sleep changes. Watch carefully for mood/behavior changes; FDA Black Box warning for suicidal ideation particularly relevant in adolescents.

Target dose 1.2 mg/kg/day reached around day 7-14 after titration from starting dose. Full therapeutic effect requires 4-6 weeks at target dose for assessment. Response evaluation includes ADHD symptom improvement, school performance, homework completion, family functioning, social functioning, and self-esteem changes.

Maximum dose 1.4 mg/kg/day OR 100 mg total daily (whichever lower) considered when target dose inadequate after 4-6 weeks with tolerable side effects. Do NOT escalate to maximum if no response at target (Strattera may not be right medication), significant side effects at target, growth concerns, cardiovascular concerns, or mood concerns.

Age 6-12 considerations: smaller children with smaller doses and more challenging capsule swallowing; behavioral observation by parents/teachers primary monitoring; mood changes may manifest as behavioral changes; growth particularly important at this age; school nurse coordination, teacher awareness, possible 504 plan/IEP considerations.

Age 13-17 considerations: significant growth spurts requiring dose adjustments; hormonal changes; FDA Black Box for suicidal ideation particularly relevant; adolescent autonomy in treatment decisions; substance use considerations (alcohol, cannabis); transition to adult care preparation; growing into adult dosing protocol around 70+ kg.

Growth monitoring protocol: baseline height/weight; monthly weight initially; quarterly height; annual growth chart review; track on standardized growth chart. Concerning patterns: >5% weight loss, failure to gain expected weight, decreased height velocity, BMI dropping into underweight, crossing two major percentiles downward. Interventions: nutritional support, timing optimization, dose reduction consideration, possible endocrinology consultation.

Long-term growth outcomes: most children reach expected adult height with possible slight reduction; catch-up growth common when treatment discontinued or adjusted; individual variation substantial; family monitoring important beyond clinical visits. Nutritional strategies: substantial breakfast before dose, calorie-dense snacks, smoothies/milkshakes, protein focus, family dinner emphasis.

The Weight-to-Dose Conversion Reference provides 16-row comprehensive table covering 18-80+ kg with starting, target, and maximum doses for each weight range — practical reference for parents and prescribers.

School communication essential: school nurse awareness, teacher observation of behavior and academic performance, possible 504 plan or IEP accommodations, parent-teacher conferences, privacy considerations. Strattera generally taken at home morning; minimal school-administered medication required.

Pediatric side effect profile: most common decreased appetite/nausea/fatigue/headache/mood changes/sleep changes/weight loss; less common but important suicidal ideation (FDA Black Box), aggression, psychotic symptoms, mania, liver function abnormalities. Immediate prescriber contact for: suicidal thoughts, significant mood changes, aggression escalation, hallucinations, liver concerns, severe symptoms, allergic reactions.

The Parent Guidance note: full effect takes 4-6 weeks; side effects appear before benefits; rocky start common; track behavior/school/mood in daily diary for prescriber discussion; immediate contact for concerning mood/behavior changes especially suicidal thoughts.

For broader Strattera context and complementary topics, see Strattera Starting Dose for Adults (for comparison with pediatric protocol), Strattera 80mg vs 100mg (relevant for adolescents reaching adult dosing), Strattera and Alcohol, Strattera and Caffeine, Strattera and SSRI/SNRI, Strattera and MAOIs, Strattera and Birth Control (relevant for older adolescent girls), Strattera and Marijuana (relevant for adolescents), Strattera and Antihistamines, Strattera and Albuterol (relevant for asthmatic children), Cardiovascular Effects, Liver Health, FDA Black Box SI (critical for pediatric monitoring), Sleep Effects, Long-Term Side Effects, Weight Loss (relevant for growth concerns), Sexual Side Effects, and Withdrawal.

For Strattera comparison cluster (when considering alternatives for children): vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree.

For modafinil note: not FDA-approved for ADHD in pediatric patients; used in adolescents only off-label with specialist guidance. Modalert 200 mg primarily for adult narcolepsy/sleep disorder use.

❓ Frequently Asked Questions

📚 References & Further Reading

• FDA prescribing information for Strattera (atomoxetine) — pediatric dosing protocol.
• American Academy of Pediatrics — ADHD treatment guidelines for children and adolescents.
• American Academy of Child and Adolescent Psychiatry — pediatric ADHD treatment.
• National Institute of Mental Health — pediatric ADHD overview.
• CDC growth charts — standardized pediatric growth assessment.
• Clinical Pharmacogenetics Implementation Consortium — CYP2D6 atomoxetine pediatric guidance.
• FDA Black Box warning — atomoxetine suicidal ideation in pediatric patients.
• Strattera dosing protocol cluster: Adult Starting Dose, 80mg vs 100mg
• Strattera lifestyle/interaction cluster: Alcohol, Caffeine, SSRI/SNRI, MAOIs, Birth Control, Marijuana, Antihistamines, Albuterol
• Strattera safety cluster: Long-Term, Cardiovascular, Liver Health, FDA Black Box SI, Sleep, Weight Loss, Sexual Side Effects, Withdrawal
• Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin, vs Intuniv, vs Qelbree
• Modalert 200 mg, Modvigil 200 mg, Waklert 150 mg — primary product pages (adult use primarily).
• RXshop Editorial Team — content reviewed by licensed pharmacist; for parent/caregiver education, not a substitute for individual pediatric medical consultation.